Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
In November last year DSM announced that it will combine its pharmaceutical products business (DPP) with contract manufacturing organisation Patheon, bringing to an end several years of efforts to find a partner for the underperforming division .
Earlier today DSM spokesman Herman Betten told BioPharma-Reporter.com that DSM Biologics – which is part of the firm’s pharmaceutical unit – will be part of the new combined company and that the recently opened biomanufacturing facility in Brisbane would be included.
The plant, which has been operational since June last year , was constructed in partnership with the Australian Institute for Bioengineering and Nanotechnology (AIBN).
Betten also said that the official name of the combined firm – which is currently being referred to as NewCo – will be revealed when the deal is completed.
DSM’s plans for DPP also featured in the Dutch firm’s results release issued earlier today. The business is now listed as a discontinued operation.
The firm said that: “DSM Pharmaceutical Products delivered an improved performance in the quarter, with good volume growth and higher prices being reflected also in good EBITDA growth.
“This performance will support a good start for the value-creating venture with JLL Partners.”